- Trials with a EudraCT protocol (174)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
174 result(s) found for: Cognitive decline.
Displaying page 1 of 9.
EudraCT Number: 2013-004984-30 | Sponsor Protocol Number: AD-4833/TOMM40_303 | Start Date*: 2015-03-04 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd | |||||||||||||
Full Title: A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Co... | |||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000473-83 | Sponsor Protocol Number: PET-tau-FACEHBI | Start Date*: 2021-12-15 |
Sponsor Name:Fundació ACE-Institut Català de Neurociències Aplicades | ||
Full Title: PET imaging study of the brain tau deposit in individuals with subjective cognitive decline and mild cognitive impairment: FACEHBI cohort. | ||
Medical condition: Subjective cognitive impairment and mild cognitive decline in evaluation for diagnosis of Alzheimer's Disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014283-19 | Sponsor Protocol Number: 575/09 | Start Date*: 2009-08-04 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Effect of remifentanil on postoperative cognitive function in patients undergoing major abdominal surgery | |||||||||||||
Medical condition: Elderly patients with risk of post operative cognitive dysfunction. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001975-12 | Sponsor Protocol Number: V00191 PO 202 | Start Date*: 2007-07-18 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT - IDPF | |||||||||||||
Full Title: Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel... | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) FI (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001850-13 | Sponsor Protocol Number: GLP-1/MCI | Start Date*: 2015-09-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA | |||||||||||||
Full Title: Long-acting exenatide: a tool to stop cognitive decline in patients with mild cognitive impairment with or without dysglycemia? | |||||||||||||
Medical condition: Moderate cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002343-29 | Sponsor Protocol Number: CRCSV2A18 | Start Date*: 2020-08-11 | |||||||||||
Sponsor Name:Service of Neurology, CHU Liege | |||||||||||||
Full Title: Synaptic modifications in subjective cognitive decline. A study using [18F]UCB-H, a synaptic vesicle 2A radiotracer. | |||||||||||||
Medical condition: Neurodegenerative Cognitive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003111-58 | Sponsor Protocol Number: AD-4833/TOMM40_301 | Start Date*: 2013-09-20 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd | |||||||||||||
Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s... | |||||||||||||
Medical condition: Mild cognitive impairment due to Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005841-13 | Sponsor Protocol Number: 65705 | Start Date*: 2007-01-25 | |||||||||||
Sponsor Name:Gedeon Richter Plc | |||||||||||||
Full Title: Multicenter, open-label study to investigate the efficacy and safety of Cavinton Forte (vinpocetine) tablet in patients with mild cognitive impairment (MCI). | |||||||||||||
Medical condition: Mild cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003188-13 | Sponsor Protocol Number: CONIVAD | Start Date*: 2016-09-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: Pilot study on the association choline alphoscerate-nimodipine in patients with subcortical vascular cognitive impairment | |||||||||||||
Medical condition: Subcortical vascular cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011582-88 | Sponsor Protocol Number: 41470956 | Start Date*: 2009-05-28 | |||||||||||
Sponsor Name:St James Hospital | |||||||||||||
Full Title: The differential effects of donepezil and placebo on EEG/ ERP measures and fMRI in mild cognitive impairment and elderly controls | |||||||||||||
Medical condition: Amnestic Mild cognitive Impairment (aMCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000434-21 | Sponsor Protocol Number: LP1 | Start Date*: 2005-06-15 |
Sponsor Name:Kognitive Neurologie, Institut für Medizin, Forschungszentrum Jülich | ||
Full Title: Neurochemische Modulation von Exekutiv- und Gedächtnisfunktionen | ||
Medical condition: Progressive cognitive decline in physiological aging | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001436-35 | Sponsor Protocol Number: COFITAGE2016 | Start Date*: 2017-01-06 |
Sponsor Name:Service of Neurology, CHU Liege | ||
Full Title: How sleep and circadian rhythmicity promote cognitive fitness and protect against cognitive decline in the elderly population | ||
Medical condition: Healthy middle aged (50 - 70 y.o.) individual with and without preclinical Alzheimer's disease defined by biomarkers | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002277-22 | Sponsor Protocol Number: AMYPAD-02 | Start Date*: 2018-09-12 |
Sponsor Name:Stichting VUmc | ||
Full Title: AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study in individuals without dementia to evaluate the additional value of quantitative amyloid im... | ||
Medical condition: Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) ES (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006203-36 | Sponsor Protocol Number: NL21082.000.08 | Start Date*: 2007-05-23 | |||||||||||
Sponsor Name:Academic Medical Centre (AMC) | |||||||||||||
Full Title: Dopaminergic neurotransmission and cognitive decline in velocardiofacial syndrome | |||||||||||||
Medical condition: Dementia in velocardiofacial syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003451-30 | Sponsor Protocol Number: Euro-SCD-FBB2 | Start Date*: 2017-02-14 | |||||||||||
Sponsor Name:Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) | |||||||||||||
Full Title: Subjects with subjective cognitive decline: 18F-Florbetaben Positrón Emission Tomography Study. | |||||||||||||
Medical condition: Subjects with subjective cognitive decline. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004671-12 | Sponsor Protocol Number: s55892 | Start Date*: 2014-06-20 |
Sponsor Name:University of Leuven | ||
Full Title: Predictive value of biomarkers in patients with amnestic mild cognitive impairment | ||
Medical condition: Mild cognitive impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006195-39 | Sponsor Protocol Number: EarlyAD-PET | Start Date*: 2012-02-29 | |||||||||||||||||||||
Sponsor Name:Skånes universitetssjukhus | |||||||||||||||||||||||
Full Title: An open-label study to compare the prognostic value of (18F)Flutemetamol PET-imaging with longitudinal biomarker data in healthy volunteers and patients with mild cognitive impairment | |||||||||||||||||||||||
Medical condition: Dementia and cognitive impairment; in particular mild cognitive impairment and Alzheimer's disease | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: SE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000762-29 | Sponsor Protocol Number: COLAL/11/2016 | Start Date*: 2017-10-09 | ||||||||||||||||
Sponsor Name:MDM S.P.A. | ||||||||||||||||||
Full Title: CHOLINA ALPHOSCERATE INJECTION VERSUS CITICOLINE INJECTION IN ELDERLY PATIENTS WITH COGNITIVE IMPAIRMENT RESULTING FROM CEREBROVASCULAR EVENT | ||||||||||||||||||
Medical condition: Cognitive impairment resulting from cerebrovascular event. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001184-39 | Sponsor Protocol Number: FBPASL5-01 | Start Date*: 2015-09-17 | |||||||||||
Sponsor Name:ASL 5 SPEZZINO | |||||||||||||
Full Title: Assessing Florbetaben PET Patterns in MCI Patients for an Improved Prediction of Conversion to AD | |||||||||||||
Medical condition: Mild Cognitive Impairment | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005024-37 | Sponsor Protocol Number: 202100647 | Start Date*: 2022-01-24 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease | ||
Medical condition: - Alzheimer's disease - Mild Cognitive Impairment - Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
